<DOC>
	<DOCNO>NCT02342782</DOCNO>
	<brief_summary>This phase I trial study side effect best dose yttrium Y 90 basiliximab give together standard combination chemotherapy stem cell transplant treat patient mature T-cell non-Hodgkin lymphoma . Radioactive substance link monoclonal antibody , yttrium Y 90 basiliximab , bind cancer cell give radiation may help kill cancer cell . Drugs use chemotherapy , carmustine , cytarabine , etoposide , melphalan ( BEAM ) , work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . Giving yttrium Y 90 basiliximab chemotherapy stem cell transplant may help kill cancer cell body help make room patient 's bone marrow new blood-forming cell ( stem cell ) grow . Stem cell collect patient 's blood store treatment later return patient replace blood-forming cell destroy .</brief_summary>
	<brief_title>Yttrium Y 90 Basiliximab Combination Chemotherapy Before Stem Cell Transplant Treating Patients With Mature T-cell Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine administration 90Y-basiliximab/DOTA ( yttrium Y 90 basiliximab ) , give combination standard dose BEAM , condition autologous hematopoietic cell transplant ( AHCT ) , safe , evaluation toxicity , include type , frequency , severity , attribution , time course duration . II . To determine maximum tolerate dose ( MTD ) 90Y-basiliximab/DOTA give combination standard dose BEAM , patient T-cell non-Hodgkin lymphoma ( T-NHL ) part condition AHCT . SECONDARY OBJECTIVES : I . To characterize evaluate hematologic recovery term neutrophil platelet engraftment time . II . To estimate radiation dos whole body normal organ serial image study . III . To estimate overall survival , progression-free survival , non-relapse mortality cumulative incidence relapse/progression 100-days ( non-relapse mortality [ NRM ] ) , 1-year 2-years . OUTLINE : This dose-escalation study yttrium Y 90 basiliximab . Patients receive yttrium Y 90 basiliximab intravenously ( IV ) day -21 -14 , carmustine IV 1-2 hour day -7 -6 , etoposide IV twice daily ( BID ) day -5 -2 , cytarabine IV BID day -5 -2 , melphalan IV day -1 . Patients undergo autologous hematopoietic stem cell transplant day 0 . After completion study treatment , patient follow 30 , 100 , 180 day 1 , 1.5 , 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients pathologically confirm diagnosis systemic mature Tcell nonHodgkin lymphoma ( NHL ) City Hope pathology review per World Health Organization ( WHO ) classification lymphoma 2008 , deem eligible high dose therapy AHCT include patient : * TNHL histology include peripheral Tcell lymphoma ( PTCLs ) , cutaneous Tcell lymphoma ( CTCLs ) natural killer ( NK ) /T cell lymphoma First remission initial firstline therapy ( CR1 ) PTCL patient , except anaplastic lymphoma receptor tyrosine kinase ( ALK ) + anaplastic large cell lymphoma ( ALCL ) CTCL ; patient minimal residual disease induction therapy may also eligible discretion principal investigator ( PI ) Relapsed/refractory disease , stable disease , partial remission ( PR ) complete remission ( CR ) , receive least 2 line therapy , adequate allogenetic stem cell transplant option Life expectancy &gt; = 6 month Karnofsky status &gt; = 70 % Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control abstinence ) prior study entry six month follow duration study participation ; woman become pregnant suspect pregnant participate trial , inform treat physician immediately Cardiac ejection fraction &gt; = 50 % echocardiogram multi gate acquisition scan ( MUGA ) Forced expiratory volume one second ( FEV1 ) &gt; 65 % predict measured , diffuse capacity lung carbon monoxide ( DLCO ) &gt; 50 % predict measured Bilirubin &lt; 1.5 x normal except case abnormal liver function test ( LFTS ) due involvement TNHL Serum glutamic oxaloacetic transaminase ( SGOT ) AND serum glutamate pyruvate transaminase ( SGPT ) &lt; 2 x normal except case abnormal LFTS due involvement TNHL Serum creatinine &lt; 1.5 mg/dL , measure creatinine clearance &gt; 60 mL/min Patients enrol collection least 3.0 x 10^6 CD34 cells/kg autologous hematopoietic progenitor cell ( HPCA ) apheresis ; minimum 2 collection procedure require , unless collection day # 1 &gt; 5.0 x 10^6 , CD34 cells/kg ; maximum 10 collection allow ; bone marrow harvest supplement apheresis allow Recovery nonhematologic toxicity salvage cytoreductive chemotherapy = &lt; grade 2 ( Common Terminology Criteria Adverse Events [ CTCAE ] version 4 [ v4 ] ) Body mass index ( BMI ) &gt; 35 % consider casebycase basis Radiation Oncology principal investigator ( P.I . ) All subject must ability understand willingness sign write informed consent Systemic chemotherapy radiation give within 4 week prior Y90 dose radioimmunotherapy ( RIT ) , exception single agent cyclophosphamide prim chemotherapy administer mobilization Progressive disease Patients uncontrolled illness include ongoing active infection require therapy Patients may receive investigational agent , concurrent biological , chemotherapy , radiation therapy ; may receive experimental agent prior enrol trial History allergic reaction attribute compound similar chemical biologic composition basiliximab Pregnant woman exclude study ; breastfeed discontinue mother treated indium In 111 ( 111In ) 90YbasiliximabDOTA Prior high dose chemotherapy autologous hematopoietic cell transplantation prior allogeneic transplantation Significant prior external beam doselimiting radiation critical organ base review prior radiation treatment record Radiation Oncology PI ; patient prior external beam radiation &gt; 2000 cGy ( 180 200 cGy per day ) lung ineligible ; patient ANY prior radiation heart ineligible ; patient &gt; 500 cGy kidney exclude study ; Note : patient electron beam therapy still eligible evaluated case case basis Radiation Oncology PI Presence antibody basiliximab serum ( required patient receive prior antibody ) Myelodysplasia active malignancy TNHL , &lt; 5 year remission prior malignancy , except adequately treat basal cell squamous cell carcinoma Active hepatitis B C viral infection hepatitis B surface antigen positive Patients detectable human immunodeficiency virus ( HIV ) viral load HIVpositive AND resistant genotype Patients psychosocial circumstance illness preclude protocol participation ( determine P.I . ) Any cytogenetic abnormality bone marrow know associated predictive myelodysplasia exclude ; include , limited , del ( 5 ) , del ( 7 ) , del ( 11 ) Evidence marrow disease flow morphology upfront salvage cytoreductive therapy stem cell mobilization Bone marrow ( BM ) harvest require reach adequate cell dose transplant Subjects , opinion investigator , may able comply safety monitoring requirement study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>